Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Adoptive therapies: quo vadis?

J W Clark1, D L Longo

  • 1Division of Cancer Treatment, National Cancer Institute, Frederick, Md.

Pathology and Immunopathology Research
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Endothelial cells require functional FLVCR1a during developmental and adult angiogenesis.

Angiogenesis·2023
Same author

Complete on/off responsive ParaCEST MRI contrast agents for copper and zinc.

Dalton transactions (Cambridge, England : 2003)·2018
Same author

Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma.

Clinical pharmacology and therapeutics·2016
Same author

A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.

Leukemia·2014
Same author

p52-Independent nuclear translocation of RelB promotes LPS-induced attachment.

Biochemical and biophysical research communications·2009
Same author

Synergistic effect of AS101 and Bryostatin-1 on myeloid leukemia cell differentiation in vitro and in an animal model.

Leukemia·2007

Adoptive immunotherapy using interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells shows promise for melanoma and renal cell carcinoma. Research is optimizing IL-2/LAK therapy and exploring novel approaches for enhanced cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Cancer Therapy

Background:

  • Adoptive immunotherapy with interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells has shown success in treating melanoma and renal cell carcinoma.
  • Ongoing research aims to optimize IL-2/LAK therapy and develop more effective immunotherapy strategies.
  • Clinical trials are investigating various aspects of IL-2 dose, schedule, and cell culture conditions.

Purpose of the Study:

  • To explore strategies for optimizing adoptive immunotherapy using IL-2 and LAK cells.
  • To investigate novel approaches for enhancing cancer immunotherapy beyond current IL-2/LAK protocols.
  • To identify methods for inducing and expanding tumor-specific immune cells for improved antitumor activity.

Main Methods:

  • Combining IL-2 +/- LAK cells with synergistic agents like interferons, interferon inducers (poly-IC:LC, flavone-8-acetic acid), and chemotherapeutic agents (cyclophosphamide, doxorubicin, DTIC).

Related Experiment Videos

  • Developing approaches to induce and expand tumor-specific immune cells, including IL-2-expanded tumor-infiltrating lymphocytes and tumor vaccines.
  • Investigating the role of activated and expanded macrophages in adoptive cancer immunotherapy.

    • Main Results:

    • IL-2/LAK therapy has demonstrated success in a subset of patients with melanoma and renal cell carcinoma.
    • Combination therapies involving IL-2/LAK with other agents show synergistic effects.
    • Approaches to expand tumor-specific immune cells and activate macrophages are under investigation for enhanced antitumor efficacy.

    Conclusions:

    • Optimizing IL-2/LAK therapy and exploring novel immunotherapy strategies are crucial for improving cancer treatment outcomes.
    • Combination therapies and the development of tumor-specific immune responses hold significant potential for effective cancer immunotherapy.
    • Further research into the mechanisms of IL-2 and adoptive immunotherapy will lead to more refined and effective therapeutic approaches for cancer treatment.